Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

34.55USD
4:00pm EDT
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$34.55
Open
$34.50
Day's High
$34.95
Day's Low
$34.00
Volume
245,370
Avg. Vol
176,174
52-wk High
$34.95
52-wk Low
$17.25

Latest Key Developments (Source: Significant Developments)

Supernus announces Q1 earnings per share $0.19
Tuesday, 9 May 2017 04:15pm EDT 

May 9 (Reuters) - Supernus Pharmaceuticals Inc :Supernus announces first quarter 2017 financial results.Q1 earnings per share $0.19.Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.Supernus Pharmaceuticals -Q1 2017 product prescriptions for trokendi XR() and oxtellar XR, as reported by IMS, totaled 134,855, a 17.1% increase over Q1 of 2016.Supernus Pharmaceuticals Inc says net product sales for Q1 of 2017 were $56.4 million, a 31.2% increase over $43.0 million in same period prior year.Supernus Pharmaceuticals Inc sees 2017 net product sales in range of $265 million to $275 million.  Full Article

Supernus receives final FDA approval for trokendi XR
Wednesday, 5 Apr 2017 06:44pm EDT 

Supernus Pharmaceuticals Inc : Supernus receives final FDA approval for trokendi XR for migraine prophylaxis in adults and adolescents .Supernus Pharmaceuticals Inc - FDA granted final approval to co's supplemental new drug applications requesting label expansion for trokendi XR.  Full Article

Supernus announces settlement with Zydus on Trokendi XR patent litigation
Monday, 6 Mar 2017 05:31pm EST 

Supernus Pharmaceuticals Inc : Supernus announces settlement with Zydus on Trokendi XR patent litigation . Supernus intends to continue its "vigorous" enforcement of its patent rights for Trokendi XR . Settlement agreement permits Zydus to begin selling generic version of Trokendi XR on Jan 1, 2023 .Supernus announces settlement with Zydus on Trokendi XR patent litigation.  Full Article

Supernus Pharmaceuticals files for non-timely 10-K
Wednesday, 1 Mar 2017 05:36pm EST 

Supernus Pharmaceuticals Inc :Supernus Pharmaceuticals Inc - files for non-timely 10-K.  Full Article

Supernus Q4 earnings per share $0.26
Tuesday, 28 Feb 2017 07:55pm EST 

Supernus Pharmaceuticals Inc : Supernus announces record fourth quarter and full year 2016 financial results . Q4 earnings per share $0.26 . Q4 earnings per share view $0.25 -- Thomson Reuters I/B/E/S . Net product sales for Q4 of 2016 were $61.1 million, up 43.4% .Sees FY 2017 net product sales in range of $265 million to $275 million.  Full Article

Supernus announces issuance of eighth U.S. patent protecting Trokendi XR
Wednesday, 8 Feb 2017 07:00am EST 

Supernus Pharmaceuticals Inc - : Supernus announces issuance of eighth U.S. Patent protecting Trokendi XR .Says patent provides protection for product with expiration that is no earlier than 2027.  Full Article

Supernus receives Nasdaq non-compliance notice
Thursday, 17 Nov 2016 04:30pm EST 

Supernus Pharmaceuticals Inc : Supernus receives Nasdaq non-compliance notice .Supernus Pharmaceuticals says currently anticipates regaining compliance with filing requirement by filing its quarterly report prior to January 13, 2017.  Full Article

Supernus Pharmaceuticals sees 2016 net product sales in range of $205 mln to $210 mln
Monday, 14 Nov 2016 06:21am EST 

Supernus Pharmaceuticals Inc : Sees 2016 net product sales in range of $205 million to $210 million . Supernus Pharma - taking into consideration anticipated effects of restatement for FY , operating income would range from $46 million to $51 million .Supernus Pharmaceuticals - excluding anticipated effect of restatement, FY operating income would range from $42 million to $47 million.  Full Article

Supernus pharmaceuticals Inc says FY 2016 net product sales will remain in range of $200 mln- $210 mln
Tuesday, 2 Aug 2016 04:30pm EDT 

Supernus Pharmaceuticals Inc : Supernus announces second quarter 2016 financial results . Q2 revenue $50.4 million versus I/B/E/S view $49.7 million . Q2 earnings per share $0.18 . Q2 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees 2016 operating income in range of $32 million to $37 million . For full year 2016, company is reiterating guidance for net product sales .Supernus pharmaceuticals inc says fy 2016 net product sales will remain in range of $200 million to $210 million.  Full Article

Supernus reiterates guidance
Thursday, 16 Jun 2016 04:30pm EDT 

Supernus Pharmaceuticals Inc : Remains in discussions with FDA regarding its supplemental new drug application, or SNDA, for migraine . Believes that such a PDUFA date is likely to be in Q3 of 2016 . FDA requested that co resubmit Trokendi XR product label with migraine as indication in different format before completing its review . No additional new data, studies or analyses for efficacy or safety were requested by FDA . Will resubmit revised label before end of June . New PDUFA date will be assigned by FDA . At this point, company believes that such a PDUFA date is likely to be in Q3 of 2016 . For full year 2016, company reiterates its guidance for net product sales and operating income .Supernus provides update on Trokendi XR migraine SNDA and reiterates guidance.  Full Article

More From Around the Web